Filtered By:
Source: American Heart Journal
Drug: Plavix
This page shows you your search results in order of relevance.
Order by Relevance | Date
Total 43 results found since Jan 2013.
Relationship of stroke and bleeding risk profiles to efficacy and safety of dabigatran dual therapy versus warfarin triple therapy in atrial fibrillation after PCI: An ancillary analysis from the RE-DUAL PCI trial
ConclusionDabigatran dual therapy reduced bleeding events irrespective of bleeding risk category and demonstrated similar efficacy regardless of stroke risk category when compared with warfarin triple therapy.
Source: American Heart Journal - March 4, 2019 Category: Cardiology Source Type: research
Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients
Conclusions Among older patients with AF and CAD, overall warfarin use was low. Patients ≥80 years old at highest stroke risk received warfarin in similar proportions to the overall cohort. Further investigation into optimizing antithrombotic strategies in this population is warranted.
Source: American Heart Journal - October 20, 2014 Category: Cardiology Source Type: research
Trends in antithrombotic therapy for atrial fibrillation: Data from the Veterans Health Administration Health System
Conclusions Among US veterans with new AF and additional risk factors for stroke, only about half receive OAC, and the proportion is declining.
Source: American Heart Journal - September 3, 2016 Category: Cardiology Source Type: research
Vorapaxar with or without clopidogrel after non–ST-segment elevation acute coronary syndromes: Results from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome trial
Conclusions We observed no interaction between vorapaxar and clopidogrel after non–ST-segment elevation acute coronary syndromes on efficacy or safety outcomes, supporting a complementary role of protease-activated receptor 1 and P2Y12 antagonism.
Source: American Heart Journal - November 25, 2014 Category: Cardiology Source Type: research
A Randomized Trial to Compare the Safety of Rivaroxaban versus Aspirin in Addition to Either Clopidogrel or Ticagrelor in Acute Coronary Syndrome: The Design of the GEMINI-ACS-1 Phase II Study
Publication date: Available online 18 January 2016 Source:American Heart Journal Author(s): Thomas J. Povsic, Matthew T. Roe, E. Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, C. Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown ...
Source: American Heart Journal - January 19, 2016 Category: Cardiology Source Type: research
Design and Rationale for the Effects of Ticagrelor and Clopidogrel in Patients with Peripheral Artery Disease (EUCLID) Trial
Conclusions The EUCLID study is investigating whether treatment with ticagrelor versus clopidogrel, given as antiplatelet monotherapy, will reduce the incidence of cardiovascular and limb-specific events in patients with symptomatic PAD.
Source: American Heart Journal - January 30, 2016 Category: Cardiology Source Type: research
A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study
Publication date: April 2016 Source:American Heart Journal, Volume 174 Author(s): Thomas J. Povsic, Matthew T. Roe, Erik Magnus Ohman, Philippe Gabriel Steg, Stefan James, Alexei Plotnikov, Hardi Mundl, Robert Welsh, Christoph Bode, Charles Michael Gibson Dual antiplatelet therapy (DAPT), the combination of aspirin and a P2Y12 inhibitor, given for 12 months remains the standard of care after presentation with acute coronary syndrome (ACS) because it has been shown to be associated with a significant reduction in ischemic events compared with aspirin monotherapy. The factor Xa inhibitor rivaroxaban was shown to ...
Source: American Heart Journal - February 23, 2016 Category: Cardiology Source Type: research
Evaluation of the Safety and Efficacy of an Edoxaban-based Antithrombotic Regimen in Patients with Atrial Fibrillation Following Successful Percutaneous Coronary Intervention (PCI) with Stent Placement: Rationale and Design of the ENTRUST-AF PCI Trial
Publication date: Available online 23 October 2017 Source:American Heart Journal Author(s): Pascal Vranckx, Thorsten Lewalter, Marco Valgimigli, Jan G. Tijssen, Paul-Egbert Reimitz, Lars Eckardt, Hans-Joachim Lanz, Wolfgang Zierhut, Rüdiger Smolnik, Andreas Goette Background The optimal antithrombotic treatment after percutaneous coronary intervention (PCI) with stenting in patients with atrial fibrillation (AF) is unknown. In the ENGAGE AF-TIMI 48 trial, edoxaban was non-inferior to a vitamin-K antagonist (VKA) with respect to the prevention of stroke or systemic embolism and was associated with significantly lower rate...
Source: American Heart Journal - October 23, 2017 Category: Cardiology Source Type: research
Effect of ticagrelor on the outcomes of patients with prior coronary artery bypass graft surgery: Insights from the PLATelet inhibition and patient outcomes (PLATO) trial
Conclusions: Prior-CABG patients presenting with acute coronary syndrome are a high-risk cohort for death and recurrent cardiovascular events but have a lower risk for major bleeding. Similar to the results in no-prior-CABG patients, ticagrelor was associated with a reduction in ischemic events without an increase in major bleeding.
Source: American Heart Journal - July 29, 2013 Category: Cardiology Authors: Emmanouil S. Brilakis, Claes Held, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann, Lars Wallentin, Stefan K. James Tags: Acute Ischemic Heart Disease Source Type: research
Design and rationale for the Prevention of Cardiovascular Events in Patients With Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin–Thrombolysis in Myocardial Infarction 54 (PEGASUS-TIMI 54) trial
Conclusions: PEGASUS-TIMI 54 is investigating whether the addition of intensive antiplatelet therapy with ticagrelor to low-dose aspirin reduces major adverse cardiovascular events in high-risk patients with a history of myocardial infarction.
Source: American Heart Journal - January 8, 2014 Category: Cardiology Authors: Marc P. Bonaca, Deepak L. Bhatt, Eugene Braunwald, Marc Cohen, Philippe Gabriel Steg, Robert F. Storey, Peter Held, Eva C. Jensen, Marc S. Sabatine Tags: Trial Design Source Type: research
Rationale and design of The Intracoronary Stenting and Antithrombotic Regimen—Testing of a six-week versus a six-month clopidogrel treatment Regimen In Patients with concomitant aspirin and oraL anticoagulant therapy following drug-Eluting stenting (ISAR-TRIPLE) study
Background: An increasing number of patients undergoing coronary stenting need lifelong anticoagulation and therefore require a triple therapy typically consisting of aspirin, clopidogrel, and a vitamin K antagonist. Triple therapy confers an elevated bleeding risk as compared with dual therapy; however, omission of either antiplatelet or anticoagulation therapy might increase the risk of stent thrombosis or thrombembolic events. Although guidelines recommend a duration of dual antiplatelet therapy of 6 to 12months after drug-eluting stent (DES) implantation, the optimal duration of dual antiplatelet therapy in patients re...
Source: American Heart Journal - January 16, 2014 Category: Cardiology Authors: K. Anette Fiedler, Robert A. Byrne, Stefanie Schulz, Dirk Sibbing, Julinda Mehilli, Tareq Ibrahim, Michael Maeng, Karl-Ludwig Laugwitz, Adnan Kastrati, Nikolaus Sarafoff Tags: Trial Design Source Type: research
CYP2C19 genotype–guided antiplatelet therapy in ST-segment elevation myocardial infarction patients—Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study
Conclusion: The POPular Genetics study is the first large-scale trial comparing CYP2C19 genotype–guided antiplatelet therapy to a nontailored strategy in terms of net clinical benefit, safety, and cost-effectiveness.
Source: American Heart Journal - March 24, 2014 Category: Cardiology Authors: Thomas O. Bergmeijer, Paul W.A. Janssen, Jurjan C. Schipper, Khalid Qaderdan, Maycel Ishak, Rianne S. Ruitenbeek, Folkert W. Asselbergs, Arnoud W.J. van ‘t Hof, Willem J.M. Dewilde, Fabrizio Spanó, Jean-Paul R. Herrman, Johannes C. Kelder, Maarten J. P Tags: Trial Design Source Type: research
Extent of coronary artery disease and outcomes after ticagrelor administration in patients with an acute coronary syndrome: Insights from the PLATelet inhibition and patient Outcomes (PLATO) trial
Background: Extensive coronary artery disease (CAD) is associated with higher risk. In this substudy of the PLATO trial, we examined the effects of randomized treatment on outcome events and safety in relation to the extent of CAD.Methods: Patients were classified according to presence of extensive CAD (defined as 3-vessel disease, left main disease, or prior coronary artery bypass graft surgery). The trial's primary and secondary end points were compared using Cox proportional hazards regression.Results: Among 15,388 study patients for whom the extent of CAD was known, 4,646 (30%) had extensive CAD. Patients with extensiv...
Source: American Heart Journal - April 14, 2014 Category: Cardiology Authors: Anna Kotsia, Emmanouil S. Brilakis, Claes Held, Christopher Cannon, Gabriel P. Steg, Bernhard Meier, Frank Cools, Marc J. Claeys, Jan H. Cornel, Philip Aylward, Basil S. Lewis, Douglas Weaver, Gunnar Brandrup-Wognsen, Susanna R. Stevens, Anders Himmelmann Tags: Acute Ischemic Heart Disease Source Type: research
Ticagrelor versus clopidogrel in Asian patients with acute coronary syndrome: A retrospective analysis from the Platelet Inhibition and Patient Outcomes (PLATO) Trial
Conclusions We observed consistency of effects in Asian patients receiving ticagrelor and clopidogrel in the PLATO study. The relatively modest number of Asian patients in this analysis supports further investigation of larger cohorts to confirm our observations.
Source: American Heart Journal - April 3, 2015 Category: Cardiology Source Type: research
